ratiopharm launches the generic version of Singulair (R) for the treatment of asthma.

-Montelukast ratiopharm, generic version of the well-known treatment Singulair ®, is indicated as additional therapy in patients (each presentation is aimed at a different age range(, from 2 years) with mild persistent asthma to moderate not adequately controlled with corticosteroids, inhalados1, 2, 3

-10 mg presentation can provide symptomatic relief of allergic rhinitis estacional3, disease affecting more than 20 per cent of the population espanola4

– with this release, ratiopharm extends its vade mecum to more than 110 molecules and nearly 300 references

Madrid, March of 2013- ratiopharm, pharmaceutical company specializing in the production and marketing of generic drugs, has launched three different montelukast presentations ratiopharm EFG: 4 and 5 mg chewable tablets, and 10 mg film-coated tablets. With these presentations ratiopharm covers a wide range of age of asthmatic patients (2 to 5 years in the case of the presentation of 4 mg; aged 6 to 14 in the case of the 5 mg; and 15 years of age and older in the case of the 10 mg).

Montelukast ratiopharm EFG, generic version of the well-known treatment Singulair ®, is indicated to treat asthma as additional therapy in patients with mild persistent asthma to moderate not controlled adequately with inhaled corticosteroids, and who “on demand” short-acting agonists β provide insufficient clinical control of the asma12.3.

Montelukast submissions indicated for children from 2 to 14 years, both the presentation of montelukast for patients aged 15 years or older, are also indicated for the prophylaxis of asthma, i.e. as a preventive treatment for the symptoms of this disease, whose main component is the ejercicio1-induced bronchoconstriction2.3.

for asthmatic patients that montelukast is indicated for asthma Montelukast 10 mg tablets, coated film EFG ratiopharm can also provide symptomatic relief of allergic rhinitis estacional3, a disease that affects more than 20 per cent of the population espanola4.

With this drug, which belongs to the leucotrienos1 receptor antagonists pharmacotherapeutic group, ratiopharm expands its vade mecum, which already has more than 110 molecules and nearly 300 references.

About ratiopharm

ratiopharm S.A.U is a pharmaceutical company specializing in the production and marketing of medicines generic. ratiopharm sells a large number of molecules belonging to the most important therapeutic areas, making it one of the laboratories of generics more important in Europe. With more than 900 registered preparations, ratiopharm has one of the portfolios more extensive in the field of generic drugs, covering almost all therapeutic areas. It belongs to the TEVA Group (NYSE:TEVA), a leading pharmaceutical company globally committed to improving access to health care to developing, producing and marketing generic medicines, as well as innovative drugs and pharmaceutical specialities.

references:

1 – source datasheet promotional montelukast 4 mg ratiopharm